Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, ...

Our success across all areas of the business in 2024—most notably the delivery of positive data from the landmark Phase 3 ASPEN study of brensocatib in bronchiectasis—has positioned us to ...

The company expects to launch Brensocatib for non-cystic fibrosis bronchiectasis (NCFBE) in 2025. In a Phase 3 clinical trial, the drug achieved a 20% reduction in pulmonary exacerbations and an ...

Mepolizumab reduced clinically significant exacerbations in patients with severe asthma regardless of their atopic status, IgE levels, or BEC count. Mepolizumab effectively reduces clinically ...

Children with asthma whose interferon expression was lower at baseline had shorter time to exacerbation and an increased exacerbation risk during viral illness. Respiratory illnesses that progress to ...

ARINA-1 is under investigation for its ability to increase lung function and decrease exacerbations in NCFB patients. Leading Companies in the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market: The ...

Cefixime is commonly used to treat a variety of bacterial infections, including acute bronchitis, chronic bronchitis exacerbations, bronchiectasis with infection, secondary infections in chronic ...

“Right now, people with bronchiectasis have no approved treatments to prevent pulmonary exacerbations that define this disease and can lead to destruction of lung tissue, putting hundreds of ...